| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT | /s/ Srinivas Akkaraju | 24 Sep 2025 | 0001253170 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VTVT | Class A Common Stock | Award | $1,618,090 | +106,000 | $15.26 | 106,000 | 22 Sep 2025 | By Samsara Opportunity Fund, L.P. | F1, F2 | |
| holding | VTVT | Class A Common Stock | 206,784 | 22 Sep 2025 | By Samsara BioCapital, L.P. | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VTVT | Pre-Funded Warrants (Right to Buy) | Award | +877,214 | 877,214 | 22 Sep 2025 | Class A Common Stock | 877,214 | $0.0100 | By Samsara Opportunity Fund, L.P. | F1, F2, F4 | |||
| transaction | VTVT | Warrant (Right to Buy) | Award | +983,214 | 983,214 | 22 Sep 2025 | Class A Common Stock | 983,214 | $22.71 | By Samsara Opportunity Fund, L.P. | F1, F2, F5 | |||
| holding | VTVT | Pre-Funded Warrants (Right to Buy) | 1,548,101 | 22 Sep 2025 | Class A Common Stock | 1,548,101 | $0.0100 | By Samsara BioCapital, L.P. | F3, F4 | |||||
| holding | VTVT | Warrant (Right to Buy) | 655,523 | 22 Sep 2025 | Class A Common Stock | 655,523 | $22.71 | By Samsara BioCapital, L.P | F3, F5 |
| Id | Content |
|---|---|
| F1 | On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. |
| F2 | Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
| F3 | These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
| F4 | The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. |
| F5 | The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. |